Purpose: There is no positive evidence for the efficacy of antiemetic triplet therapy with aprepitant (APR), palonosetron (PALO), and dexamethasone (DEX) for moderate emetogenic chemotherapy, especially for gynecologic malignancies. Thus, the present study evaluated the efficacy of this triplet therapy in patients receiving carboplatin and paclitaxel (CP) for gynecologic malignancy.
Methods: Seventy patients with gynecologic cancer receiving CP were enrolled into a prospective single-arm study with APR (125 mg on day 1, 80 mg on days 2-3), PALO (0.75 mg), and DEX (20 mg) before initiating chemotherapy. The primary endpoint was delayed complete response (CR) rate, i.e., no vomiting and no rescue, at 24-120 h after chemotherapy administration.
Results: Seventy patients were enrolled. The delayed CR rate was 97.1% (68/70). No serious adverse events were observed. Younger patient age (≤50 years) tended to be associated with a poor delayed CR rate.
Conclusions: This study demonstrated a notable efficacy of antiemetic triplet therapy with APR, PALO, and DEX in female patients receiving CP. Further evaluation with a larger phase III trial is warranted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00520-017-3607-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of Metastatic Colorectal Cancer (mCRC): Real-World Recommendations.
South Asian J Cancer
October 2024
Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India.
Introduction: Metastatic CRC is considered as a heterogenous disease. Its management is therefore complex and dynamic. In order the give a ready reference to community oncologists, we developed this real world recommendations.
View Article and Find Full Text PDFMatching-Adjusted Indirect Comparison of Daratumumab-Pomalidomide-Dexamethasone and Pomalidomide-Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
February 2025
Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Jeollanam-do, South Korea. Electronic address:
Background: Standard-of-care treatment for patients with multiple myeloma (MM) typically includes frontline lenalidomide until disease progression, making lenalidomide-refractoriness a challenge in relapsed/refractory MM (RRMM). Lenalidomide-sparing triplet therapies, daratumumab, pomalidomide, and dexamethasone (DPd) and pomalidomide, bortezomib, and dexamethasone (PVd), demonstrated efficacy in lenalidomide-exposed patients in the APOLLO and OPTIMISMM trials, respectively. Without head-to-head trial data, we assessed the comparative effectiveness of DPd versus PVd via matching-adjusted indirect comparison (MAIC).
View Article and Find Full Text PDFComparison of PSOX (paclitaxel, oxaliplatin, S-1) and SOX (oxaliplatin, S-1) as postoperative adjuvant chemotherapy for stage II-III gastric cancer.
World J Surg Oncol
March 2025
Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, 210009, China.
Background: Adjuvant chemotherapy is the conventional treatment for stage II and III gastric cancer(GC). Postoperative doublet chemotherapy has consistently shown improved survival outcomes in advanced-stage GC patients compared to single-agent regimens. Triplet regimens have shown significant survival benefits in the perioperative settings.
View Article and Find Full Text PDFSOHO State of the Art Updates and Next Questions Acute Myeloid Leukemia: Current Status and Next Questions.
Clin Lymphoma Myeloma Leuk
February 2025
Department of Leukemia, MD Anderson Cancer Center, Houston, TX. Electronic address:
Advances in understanding leukemogenesis in acute myeloid leukemia (AML) have led to new drug approvals in the past 4 years. Ongoing preclinical research is expected to produce more targeted therapies, reducing the need for traditional chemotherapy, while also enhancing classification systems and patient prognostication. In newly diagnosed AML, the mainstay of induction still is 7+3 regimen.
View Article and Find Full Text PDFγ-Secretase modulation inhibits amyloid plaque formation and growth and stimulates plaque regression in amyloid precursor protein/presenilin-1 mice.
J Pharmacol Exp Ther
February 2025
Department of Neurology, Washington University, School of Medicine, St. Louis, Missouri.
γ-Secretase modulators (GSMs) represent an emerging oral therapy for preventing and targeting Aβ-amyloidosis in Alzheimer disease. Aβ is a family of peptides of varying lengths where both the total and relative amounts of the individual Aβ peptides affect the process of amyloidosis. In contrast to inhibitors of Aβ synthesis, GSMs do not affect the total amount of Aβ peptides generated but decrease longer more amyloidogenic Aβ species while increasing the production of shorter less amyloidogenic Aβ peptides.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!